Close Menu

NEW YORK – Immuno-oncology diagnostic firm HalioDx said Thursday that it is collaborating with the Francophone Federation of Digestive Oncology (FFCD) to select patients for a Phase II trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer.

HalioDx will use its Immunoscore in vitro diagnostic test to measure the host immune response at the tumor site by assessing lymphocytic infiltration to select patients for the multicenter POCHI trial.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.